Compare · DXCM vs GUTS
DXCM vs GUTS
Side-by-side comparison of DexCom Inc. (DXCM) and Fractyl Health Inc. (GUTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GUTS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 230.2x GUTS ($128.5M).
- Over the past year, DXCM is down 8.8% and GUTS is down 55.0% - DXCM leads by 46.2 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 2 for GUTS).
- DXCM has more recent analyst coverage (25 ratings vs 6 for GUTS).
- Company
- DexCom Inc.
- Fractyl Health Inc.
- Price
- $76.65-1.74%
- $0.81-4.88%
- Market cap
- $29.58B
- $128.5M
- 1M return
- +4.76%
- +3.33%
- 1Y return
- -8.79%
- -55.00%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2024
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest GUTS
- Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
- Director Royan Ajay bought $19,596 worth of shares (23,000 units at $0.85), increasing direct ownership by 128% to 40,901 units (SEC Form 4)
- Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Executive Officer Rajagopalan Harith bought $18,252 worth of shares (25,000 units at $0.73), increasing direct ownership by 5% to 540,557 units (SEC Form 4)
- Director Sheffield Ian bought $25,529 worth of shares (35,000 units at $0.73) (SEC Form 4)
- SEC Form 4 filed by Director Meanwell Clive
- SEC Form 4 filed by Director Barnes Kelly Ann
- SEC Form 4 filed by Director Elia Marc
- SEC Form 4 filed by Director Thompson Christopher Charles